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Background: Human endometrial mesenchymal stem cells (EnSCs) derived from menstrual blood have mesenchymal
stem/stromal cells (MSCs) characteristics and can differentiate into cell types that arise from all three germ layers. We
hypothesized that EnSCs may offer promise for restoration of ovarian dysfunction associated with premature ovarian
failure/insufficiency (POF/POI).
Methods: Mouse ovaries were injured with busulfan and cyclophosphamide (B/C) to create a damaged ovary mouse
model. Transplanted EnSCs were injected into the tail vein of sterilized mice (Chemoablated with EnSCs group; n = 80),
or culture medium was injected into the sterilized mice via the tail vein as chemoablated group (n = 80). Non-sterilized
mice were untreated controls (n = 80). Overall ovarian function was measured using vaginal smears, live imaging,
mating trials and immunohistochemical techniques.
Results: EnSCs transplantation increased body weight and improved estrous cyclicity as well as restored fertility in
sterilized mice. Migration and localization of GFP-labeled EnSCs as measured by live imaging and immunofluorescent
methods indicated that GFP-labeled cells were undetectable 48 h after cell transplantation, but were later detected in
and localized to the ovarian stroma. 5’-bromodeoxyuridine (BrdU) and mouse vasa homologue (MVH) protein
double-positive cells were immunohistochemically detected in mouse ovaries, and EnSC transplantation reduced
depletion of the germline stem cell (GSCs) pool induced by chemotherapy.
Conclusion: EnSCs derived from menstrual blood, as autologous stem cells, may restore damaged ovarian
function and offer a suitable clinical strategy for regenerative medicine.
Keywords: Endometrial mesenchymal stem cells (EnSCs), Menstrual blood, Ovarian function, Premature ovarian
failure/insufficiency (POF/POI), Chemotherapy, Germline stem cells (GSCs)Background
Cancer patients—especially women younger than 40 years
of age—who receive chemotherapy or radiation often
suffer reproductive damage. This damage is frequently
associated with premature ovarian failure/insufficiency
(POF/POI) and infertility due to ovarian germ cell tox-
icity. Alkylating agents such as cyclophosphamide (Cy)* Correspondence: laidongmei@hotmail.com; cxiang@zju.edu.cn
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unless otherwise stated.carry the greatest risk of POF/POI of all chemothera-
peutic drug classes [1-3]. Recently Kalich-Philosoph and
colleagues reported that Cy treatment activates growth
of the quiescent primordial follicle population in mice
and depletes the ovarian reserve, leading to early ovar-
ian failure and infertility [4]. Busulfan, another antineo-
plastic alkylating agent, is known to affect female
reproduction via ovarian cytotoxicity. A single injection
of 40 mg/kg busulfan in mice leads to small follicle
depletion and completely oocyte loss and it is dose-
dependent [5, 6]. In rats, primordial and primary ovar-
ian follicles of offspring were affected and caused oocyteis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7]. It is primarily believed that dormant primordial
follicles were a nonrenewable population representing
the “ovarian reserve” of reproductive potential [8]. Acti-
vation of the primordial follicle initiates unidirectional
and irreversible growth, inducing either ovulation or
atresia [9]. Thus, long-term maintenance of most folli-
cles in a dormant state is important to preserve the
primordial follicle stockpile and restore ovarian func-
tion during cancer treatment.
Stem cells are attractive because they are self-renewing
and have the potential to differentiate into all three germ
layers. Recent interest in the therapeutic potential of
stem cells has grown and multipotent stem cells could
be developed from different sources, such as bone mar-
row [10-12], adipose tissue [13, 14], amniotic fluid [15],
and the amnion [16], and all have been shown to have
the potential to restore ovarian function and rescue
long-term fertility in chemotherapy-treated female mice.
Recently, a novel stem cell source has the superiority
to conventional sources. Human endometrial mesenchy-
mal stem cells (EnSCs) with mesenchymal stem/stromal
cells (MSCs) characteristics have been isolated from
menstrual blood which lines the uterus and regenerates
after each menstrual cycle. EnSCs can rapidly grow
in vitro and have been shown to be positive for MSCs
markers, including SSEA-4, OCT4, CD9, CD29, CD105,
and CD73, although they do not express markers such
as CD34, CD45, CD133 and HLA class II. Under specific
conditions, EnSCs also undergo multipotent differenti-
ation into various functional cells, including cardiomyo-
cytes, respiratory epithelial cells, neurocytes, myocytes,
endothelial and pancreatic cells, hepatocytes, adipocytes,
and osteocytes [17-19]. A major advantage of EnSCs is
the ease of collection via non-invasive methods and effi-
cient, noncontroversial extraction that is autologous.
The fact that this novel cell population can be routinely
and safely isolated suggests a stem cell source from
child-bearing women. Additionally, several recent inves-
tigations suggest an in vivo regenerative potential of
EnSCs to treat many diseases, such as multiple sclerosis,
a murine model of stroke, and models of cardiovascular
disorders and liver injury [20-23]. Studies also show that
EnSCs can modulate allogeneic proliferation of mono-
nuclear cells in a dose-dependent manner which may be
viewed as a potential therapeutic approach for allogeneic
transplantation [24].
Considering that EnSCs have characteristics of MSCs,
we hypothesized that human menstrual blood-derived
EnSCs may also retain the ability to restore ovarian
function. Therefore, in this study, we transplanted hu-
man EnSCs via the tail vein into chemotherapy-induced
sterilized mice and measured restorative effects on ovar-
ian function. Data suggest that transplantation of humanEnSCs derived from human menstrual blood may im-
prove ovarian function and hold promise for reproduct-
ive medicine in the future.
Materials and methods
Cell sources and culture
A human EnSC line was isolated from menstrual blood
of a 40-year-old Chinese woman after written informed
consent was obtained [19, 23]. Briefly, human men-
strual blood was collected using a Divacup (E-vans
Biotech, Hangzhou, China) during the first day of
menstruation. Mononuclear cells were separated by
Ficoll-Paque (1.077 g/mL, Fisher Scientific, Portsmouth,
NH) density-gradient centrifugation according to the
manufacturer’s instructions. The purified mononuclear
cells were cultured in the Chang Medium [18] overnight
at 37 °C in 5 % CO2. Cells were trypsinized, subcultured,
and passaged every 4–6 days. Cells were used for experi-
ments until they reached 80–90 % confluence.
Human cells project were approved by the Ethics
Committee of the International Peace Maternity and
Child Health Hospital, Shanghai Jiaotong University,
Shanghai, China (Permit number: 2013–11).
Flow cytometry
Expression of cell surface markers CD29, CD90, CD34,
CD45, CD117, HLA-DR, and OCT4 were measured in
EnSCs. Cells (1 × 106) were suspended in 2% BSA/PBS
and labeled with PE anti-human CD90, PE anti-human
CD29, PE anti-human CD34, FITC anti-human CD45
(all purchased from Beckman Coulter Company, France),
and anti-human OCT4 (eBioscience, San Diego, CA).
Immunoglobulin isotype (eBioscience) incubation was
performed as a negative control. Flow cytometry was
performed using a FC500 flow cytometer (Beckman
Coulter, Fullerton, CA) and analyzed using Beckman
Coulter CXP software.
EnSC differentiation
EnSCs were cultured and induced with human mesen-
chymal stem cell functional identification kit (R&D
System, Minneapolis, Minnesota, USA) as instructed by
the manufacturer. Cells were then fixed in 4 % formal-
dehyde. For osteogenic marker, cells were stained with
Alizarin red for 5 min. For chondrogenic differentiation,
cells were stained with Alcian blue for 30 min. For
adipogenic differentiation, cells were stained with Oil
Red O for 30 min [19].
Animals
C57BL/6 wild-type female mice (n = 240; 6 weeks of age;
18.3 ± 0.1 g) were purchased from Shanghai SLAC
Laboratory Animal Co., Ltd. Of these, 160 were sterilized
by intraperitoneal injection of busulfan (Sigma-Aldrich, St.
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phosphamide (Sigma-Aldrich, 120 mg/kg; resuspended in
DMSO) [15, 16] and were observed for 1 week (n = 160,
18.2 ± 0.3 g). Then, 80 age-matched females injected with
DMSO only served as non-sterilized normal controls
(n = 80, 18.2 ± 0.2 g). All animal procedures were ap-
proved by the Institutional Animal Care and Use Com-
mittee of Shanghai, and were performed in accordance
with the National Research Council Guide for Care and
Use of Laboratory Animals. The protocol was approved
by the Committee on the Ethics of Animal Experiments
of Shanghai Jiaotong University. All surgery was per-
formed under sodium pentobarbital anesthesia, and
mice were placed on a heating plate to maintain body
temperature till the recovery.
Animal methods
EnSCs were grown to a density of 85 %, and were in-
fected with enhanced green fluorescent protein (EGFP, a
gift from Tianjin Liu) [25] with lentivirus at multiplicity
of infection (MOI) of 10. After growing for another two
days, EnSCs were examined by flow cytometry. The
overall cell transfection rate was determined to be
greater than 95 %, Then EnSCs were washed three times
and trypsinized, neutralized in 10 % FBS, washed with
phosphate-buffered saline (PBS) and resuspended in the
culture medium.
Animals were anesthetized with pentobarbital sodium
(45 mg/kg, ip). Next, approximately 20 μL of cell suspen-
sion containing 2 × 106 EnSCs of 5th passages (Chemoab-
lated with EnSCs group; n = 80), or 20 μL of culture
medium (Chemoablated group; n = 80) were injected into
the recipients via the tail vein 1 week after chemotherapy.
Non-sterilized mice were untreated controls (n = 80).
One week after injection of EnSCs, vaginal smears
were obtained at 9:00 am daily for 2 months from un-
treated control, chemoablated with EnSCs groups, and
chemoablated group animals to observe diestrus, proes-
trus, estrus and metestrus. Papanicolaou staining was used
to evaluate the estrous cycle as previously described [26,
27] and animals in each sub-stage were quantified.
After intravenous EnSC injection, animals of three
groups were weighed. Then, 1 to 8 weeks after cell trans-
plantation, animals were euthanized under anesthesia. Or-
gans (heart, liver, kidney, spleen, and ovary) from all
animals were collected and fixed with 4 % paraformalde-
hyde (4 °C, overnight), dehydrated through a graded etha-
nol series, vitrified in xylene, embedded in paraffin, and
then stained with hematoxylin and eosin (H&E).
For mating trials, 8 weeks after chemotherapy, EnSC-
treated (n = 10) and chemoablated females (n = 10) were
housed with proven fertile males for 3 months at a ratio
of 1:2. Then, the number of offspring per litter was
recorded.Live imaging of transplanted EnSCs in mice
Next, 6 h to 14 days after tail vein injection of GFP
transfected EnSCs, treated (n = 18) and untreated mice
(n = 18) were screened with a live imaging system (eX-
plore Optix, GE Company) to characterize, quantify and
visualize GFP (+) cells. The detected signal is very weak
because of the fur, so the mice were anesthetized and
abdominal cavity were opened to detect the signal.
Immunofluorescent staining
Ovaries from three groups animals were fixed with an
optimal cutting temperature (OCT) compound (Sakura
Finetek Middle East, Dubai, United Arab Emirates) and
5-μm-thick fresh sections were made. Slides were
washed twice with PBS and incubated with blocking so-
lution for 30 min at room temperature. Sections were
incubated overnight at 4 °C with rabbit polyclonal anti-
GFP (dilution 1:200; Chemicon, Billerica, MA), rabbit
anti-human polyclonal FSHR (1:100, Abcam, Cambridge,
UK), mouse anti-human nuclear monoclonal antibody
(dilution 1:50; Millipore), mouse monoclonal anti-BrdU
(1:200 dilution; Lab Vision Corporation) or rabbit anti-
human polyclonal MVH (VASA homolog, MVH; DEAD
box protein 4, DDX4; 1:100, ab13840, Abcam) [27]. Then,
sections were washed three times with 1 × PBS, and
probed with FITC-labeled IgG (1:200, Santa Cruz, CA) or
Rhodamine (TRITC)-labeled IgG (1:100, Invitrogen, Carls-
bad, CA). Fluorescent images were obtained with a Leica
DMI3000 microscope.
Histomorphometric analysis of the ovarian follicles and
germline stem cells (GSCs)
Ovaries were fixed by 10 % formalin, paraffin embedded,
serially sectioned (8 μm), aligned in order on glass
microscope slides, and stained with hematoxylin and
picric methyl blue. The number of non-atretic or atretic
primordial, primary and preantral follicles was then
determined, as described previously [12]. Immature folli-
cles were scored as atretic if the oocyte was degenerating
(convoluted, condensed) or fragmented. Grossly atretic
immature follicles lacking oocyte remnants were not in-
cluded in the analyses.
For GSCs counting, recipient mice were injected with
BrdU (50 mg/kg) and ovaries were collected 1 h later for
dual immunofluorescent analysis of BrdU incorporation
and MVH expression as described above. The presence
of BrdU–MVH double-positive cells in the ovarian was
assayed in different groups.
Statistical analysis
Animal weight, folicles and GSCs counting were quanti-
fied across groups and compared by ANOVA using
Microsoft Excel software and differences were consid-
ered statistically significant when P < 0.05. Offspring
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Wallis test. Differences were considered statistically sig-
nificant when P < 0.05 or < 0.01 (pairwise comparison).
Results
Characterization of established human EnSCs
Human EnSCs line was derived from menstrual blood of a
40-year-old Chinese woman [19, 23]. The cells grew rapidly
in vitro and were morphologically similar to fibroblast-like
cells (Fig. 1A-B) and the double time is 24 hours. Cells were
diploid without chromosomal aberrations as measured by
karyotype analysis at passage 20 (Fig. 1C).
Flow cytometry was used to detect the phenotype of
the 5th passage of EnSCs. Fig. 1D depicts cell surface
marker data. Also, human EnSCs cells were multipotent,
as indicated by their ability to differentiate into adipo-
cytes, chondroblasts and osteoblasts (Fig. 1E).
These data suggest that human EnSCs had characteris-
tics of MSCs.
Human EnSCs transplantation increased weight and
improved cyclicity of sterilized mice
To assess whether human EnSCs transplantation could
restore ovary function, wild-type female mice were ster-
ilized by pre-treatment with cyclophosphamide and bu-
sulfan to destroy the existing pre- and post-meiotic
germ cell pools as previously reported [15, 16]. These
mice were used as recipients. EnSCs grown to 85% dens-
ity were infected with green fluorescent protein (GFP)
lenti-virus (Fig. 1A-B). After infection and culture for
1 week, 2 × 106 cells were transplanted by tail vein injec-
tion into recipient females 7 days after chemotherapy.
No transplant-related deaths occurred. We observed a
significant increase in body weight in EnSCs-treated ani-
mals compared with chemoablated group from the 4th
week onward after cell transplantation (P < 0.01, Fig. 2A).
There was no difference in untreated control and
EnSCs-treated group (Fig. 2A).
One week after transplantation, vaginal smears from
chemoablated with EnSCs group began to change and
did so throughout the experiment. All diestrus, proes-
trus, estrus and metestrus cycle stages were observed in
EnSCs-treated animals and animals resembled untreated
control animals 4 weeks after cell transplantation. How-
ever, cyclicity in chemoablated animals was not as regu-
lar as normal animals. Specifically, estrus cycles were
longer or shorter, and animals remained at diestrus
throughout the experiment (Figs. 2B and 3).
The changes of major organs affected by B/C treat-
ment with H&E staining were also evaluated. Besides
ovaries, the lung, heart, liver and spleen were also dam-
aged 7 days after chemotherapy. H&E staining showed
that inflammation and edema in cardiac fibroblasts,
glomerular congestion and atrophy, mesenchymal edemaand congestion, hepatic inflammatory cell infiltration,
and spleen lymphocyte proliferation. However, 14 days
after chemotherapy, organ inflammation decreased to
various degrees (Additional file 1: Figure S1). However,
ovaries affected by B/C treatment were seriously and ir-
reversibly damage (oocyte loss, fibrosis, and sterility)
(Fig. 4C and Additional file 1: Figure S1E).
Data indicate that human EnSCs transplantation in-
creased the weight of chemotherapy-sterilized mice and
the return of an estrous cycle after cell transplantation
indicated a potential ovarian functional recovery.
Human EnSCs transplantation re-established fertility in
sterilized mice
To assess the influence of human EnSCs transplantation
on fertility, sterilized female mice were mated with un-
treated males with proven fertility. According to cyclicity
results, 8 weeks after chemotherapy, mice were chosen
for the mating trial and observed for 3 months. The total
number of pregnancies per group and pups per preg-
nancy were recorded. All reproductive outcomes mea-
sured indicated that chemotherapy reduced reproductive
capability, including incidence of pregnancy and reduced
the average number of pups per pregnancy of each fe-
male mouse. Both EnSCs-treated animals (n = 10) and
untreated control (n = 10) acquired three successful
pregnancies, whereas chemoablated mice had only one
pregnancy including stillbirth (Fig. 4A and Additional
file 2: Table S1). Sterilized female mice that underwent
EnSCs transplantation had more pups per mouse than
chemoablated group (Fig. 4B and Additional file 2:
Table S1). However, compared with untreated normal
control, chemoablated with EnSCs group had signifi-
cantly fewer numbers of pups per female mouse (Fig. 4B
and Additional file 2: Table S1).
Histological examination of midline ovarian sections after
mating rounds revealed that ovaries of chemotherapy-
treated mice were smaller than those of chemoablated with
EnSCs group or untreated control (Fig. 4C). In addition,
chemoablated with EnSCs group had numerous oocytes
at all stages of development, similar to ovaries of non-
sterilized mice; however, no follicles (with the exception
of stroma) were observed in ovaries of chemoablated
mice (Fig. 4C).
Thus, these data indicate that human EnSCs trans-
plantation restored fertility in sterilized female mice.
Human EnSCs infiltrated into chemically-damaged murine
ovarian tissue and differentiated into granulosa cells
As we previously reported [15, 16], human amniotic
fluid stem cells or amniotic epithelial cells transplant-
ation has the potential to improve ovarian function of
sterilized mice. We hypothesized that human EnSCs
could home and integrate into damaged ovarian tissue.
Fig 1 (See legend on next page.)
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Fig 1 Morphology, phenotype and pluripotency of human EnSCs. a Cultured EnSCs appear to have stromal cell morphology. b GFP-transfected
EnSCs. c Normal chromosomes expressed by cells as measured by karyotype analysis at passage 20. d Mesenchymal stem cell marker expression
in EnSCs as measured by flow cytometry. e EnSCs can differentiate into adipocytes (oil red), chondroblasts (alcian blue) and osteoblasts (alizarin
red) under standard in vitro differentiating conditions (original magnification, 100x). Scale bars = 200 μm (a, b)
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transplantation, sterilized mice were screened by live im-
aging to identify GFP (+) cell tracking 6 h to 14 days
after cell transplantation. The GFP (+) cells first entered
the pelvic organs 6 to 12 h after transplantation, then
migrated to the chest 24 h after transplantation; how-
ever, the signal is too weak to be detected 48 h after cell
transplantation and few signals were detected in pelvic
organs 7 days after cell transplantation. Background sig-
nals were detected in chemoablated mice (Fig. 5A).
Immunofluorescent studies of recipient ovarian tissues
were assayed to detect human cell tracking. Although GFP
signal could not be detected 7 days after transplantation by
live imaging, GFP-stained cells were found in ovarian tissue
stroma 2 months post-transplantation. To confirm that
GFP (+) cells in recipient ovaries was derived from graftedFig. 2 Human EnSCs transplantation increased animal weight and restored
increase over the study period. Mice of EnSCs-treated groups weighed sign
onward (*P <0.01); however, there was no significant difference between u
of substages of diestrus (DE), proestrus (PE), estrus (E) and metestrus (ME) i
cell transplantation, whereas changes in untreated control animals were m
E, Chemoablated with EnSCs transplantation group, C, Chemoablated grouhuman EnSCs, we performed double-staining with GFP
and human specific nuclear antigen in recipient ovarian
sections 2 months after EnSCs transplantation. GFP (+)
staining co-localized with human anti–nuclear staining in
ovarian stroma (Fig. 5B).
To characterize grafted cells, human follicle-stimulating
hormone receptor (FSHR) was used as both a granulosa cell
marker and a human cell tracking marker. Data show that
double staining of human FSHR and GFP was detected in
cells proximal to ovarian tissue eggs 2 months after EnSCs
transplantation (Fig. 5C and Additional file 3: Figure S2 for
negative control). Furthermore, an immunochemical assay
revealed that human FSHR staining patterns were found in
cells proximal to eggs within follicles 2 months after EnSCs
transplantation, a finding consistent with immunostaining
patterns (Additional file 4: Figure S3).cyclicity in sterilized mice. a Weight of untreated mice did not
ificantly more compared with chemoablated mice from the 4th week
ntreated control and EnSCs-treated groups (P > 0.05). b The percentage
n different groups. Cyclicity was similar to normal animals 4 weeks after
aintained at diestrus throughout the experiment. U, Untreated control;
p
Fig. 3 Vaginal exfoliative cell smear and cervical mucus crystallization indicating estrous cycles of mice in different groups and at different
observed time points. At 2, 4, and 8 weeks after cell transplantation, the typical cornified epithelial (black arrow) and typical ferning patterns
(white arrow) were observed in EnSCs-treated mice, whereas cyclicity in Chemoablated animals remained unchanged
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cells and GFP+/human FSHR+ cells in the EnSCs trans-
plantation group per number of sections are depicted in
Additional file 2: Table S2. These results strongly suggest
that a portion of EnSCs-derived cells grafted to chemo-
therapeutically murine ovarian tissue and may have differ-
entiated to granulosa cells.
Human EnSCs administration improved renewal of
germline stem cells in sterilized mice
Recently GSCs have successfully been isolated from ovar-
ies of neonatal and adult mice as well as from human
ovaries, which challenges the viewpoint that the bank of
ovarian oocytes is not renewed in postnatal female mam-
mals [27-29]. However, there is still lack of knowledge of
genesis and development of GSCs in adult ovary. To iden-
tify and confirm whether EnSCs affect oogenesis in steril-
ized mice, GSCs were immunohistochemically quantified
in mouse ovaries from different treatment groups. Mor-
phological and histological analysis of 5’-bromodeoxyuri-
dine (BrdU) and mouse vasa homologue (MVH) protein
double-positive cells were used to identify GSCs [27-29].
First, we located ovarian cells positive for MVH pro-
tein, which is expressed exclusively in germ cells, using
immunohistochemistry. Similar to previous reports
[30], MVH cytoplasmic stained cells were observed
near the surface of ovaries (Additional file 5: Figure S4).
To assess the proliferative potential of MVH-positive ovar-
ian cells, female mice were injected with BrdU, and ovarieswere collected 1 h later for dual immunofluorescence ana-
lysis of BrdU incorporation and MVH expression.
Mice were sterilized with chemotherapy, observed for
1 week, and then EnSCs were transplanted. One week
later (observation period), mice were 8 weeks of age and
at this time, mice were observed for an additional
8 weeks. To better define germ-cell dynamics in EnSCs-
treated female mice, nonatretic and atretic follicles were
quantified in ovaries of C57BL/6 mice (untreated con-
trol, chemoablated group and chemoablated with EnSCs
group). Analysis of non-atretic quiescent (primordial)
and growing (primary, preantral, and antral) follicle
numbers revealed that immature follicles were gradually
lost after chemotherapy. However, EnSCs transplantation
prevented the loss of various follicular stages and dimin-
ished the number of atretic follicles during this 8-week
period (Additional file 6: Figure S5).
The presence of BrdU–MVH double-positive cells
near the ovarian surface epithelium was observed (Fig. 6)
and the numbers of GSCs in different groups were
assayed. In normal mice ~78 GSCs per ovary were found
in 8-week-old female mice and this number gradually
declined to ~56 when the mice were 15 weeks of age,
revealing that the pool of GSCs degenerating under
normal conditions. However, in ovaries of sterilized fe-
males GSCs pools decreased 64 % one week after
chemotherapy with complete GSCs loss occurring
8 weeks after chemotherapy. In treated mice, after
EnSCs transplantation, GSCs per ovary increased and
Fig. 4 EnSCs transplantation restores fertility in mice treated with chemotherapy. Reproductive outcomes were assessed over three successive
mating rounds in different mouse groups. a Offspring obtained by mating after EnSCs transplantation into mice sterilized by chemotherapy
compared with chemoablated group and untreated control. Note the stillbirth in a chemoablated mouse (Arrow). b Mean litter size per pregnant
mouse for three litters in each group. Data represent means ± standard error. n = 10 per group. **P < 0.001. c Midline histological sections of
ovaries removed after the mating rounds and stained with H&E. Scale bars = 100 μm
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GSCs pool present in normal controls 8 weeks after
EnSCs transplantation (Fig. 7A).
Thus, EnSCs transplantation reduced the depletion of
GSCs caused by chemotherapy.
Discussion
Extraction of EnSCs from menstrual blood was first re-
ported in 2008 [18] and EnSCs have also been examined
in diverse preclinical small animal models of ischemic
stroke, hind limb ischemia, and myocardial infarction
[20, 31-33]. Considering future human clinical applica-
tions, EnSCs collection is easy, non-invasive, and autolo-
gous. Recently, preliminary results of the first clinical
trial of EnSCs were reported [34].
Building on this detailed work, we studied the effects
of EnSCs transplantation into sterilized female mice and
evaluated ovarian function. EnSCs transplantation dra-
matically improved body weight and cyclicity in recipi-
ent mice compared with chemoablated mice (Figs. 2 and
3). In addition, the number of litters obtained by natural
mating was significantly increased with chemoablated
with EnSCs group compared with chemoablated mice;although fertility recovery was not complete compared
to normal untreated controls (Fig. 4). Recently similar
results were reported that human endometrial me-
senchymal stem cells could restore ovarian function by
improving the host ovarian niche [35], however, less was
paid attention to the physiological and pathological
effects in the sterilized mice following cell therapy.
Chemotherapeutic drugs such as busulfan and cyclo-
phosphamide can cause prolonged and often irreversible
azoospermia and ovarian damage in mice and humans.
Busulfan and cyclophosphamide (B/C)-treated mice had
greater apoptosis and germ cell depletion in the ovary
[36]. However, few studies have focused on the physical
conditions whereby chemotherapy induces these effects.
We observed that animal treatment with B/C resulted in
weight loss and irregular cyclicity in female mice (Figs. 2
and 3). We first noted that major organs were affected
by B/C treatment. Inflammation and edema were ob-
served in cardiac fibroblasts, liver, kidney and spleen
7 days after chemotherapy; however, 14 days after
chemotherapy, organ inflammation decreased in various
degrees (Additional file 1: Figure S1). In contrast, ovaries
affected by B/C treatment had serious, irreversible and
Fig. 5 (See legend on next page.)
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Fig. 5 Grafted human EnSCs were detected in vivo. a Sterilized mice after tail vein cell transplantation were screened by live imaging (eXplore
Optix, GE Company) for the identification of GFP-positive cell tracking in vivo. GFP (+) cells first entered the pelvic organs 6 to 12 h after transplantation,
then migrated to chest organs 24 h after transplantation. However, the signal was too weak to be detected 48 h after cell transplantation and few
signals were collected in pelvic organs 7 days after cell transplantation. Chemoablated mouse as negative control. b Human nuclear antigen was
expressed in antral follicles in recipient ovaries and co-localized with GFP staining 2 months after EnSCs transplantation. c GFP staining was co-localized
with human FSHR staining in antral follicles of recipient ovaries 2 months after EnSCs transplantation. Scale bars: (b, c) 100 μm; (b, c insets) 10 μm
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sterility (Fig. 4C and Additional file 1: Figure S1). These
data show that B/C treatment chiefly affected ovarian
function in female mice.
Many animal and human studies indicate a beneficial
effect of MSCs infusion or implantation for tissue and
organ repair. Evidence suggests that MSCs locate to sites
of tissue damage when infused intravenously, after which
they either engraft to damaged tissue or secrete bioactive
molecules that promote tissue repair [37]. For example,Fig. 6 EnSCs transplantation improves GSCs proliferation in sterilized ovarie
(arrow) were observed near the surface epithelium of mouse ovaries in: (a)
EnSCs transplantation for 2 weeks (d) EnSCs transplantation for 2 months. Aintravenous injection of bone marrow MSCs in a mouse
model of coronary artery disease (coronary vessel ligation)
significantly improved myocardial parameters after
3 weeks; however, grafted cells were not detected after
48 h [38]. In this study, we analyzed the distribution of
transplanted EnSCs, and we observed that cells localized
to pelvic organs first after intravenous tail vein injection in
sterilized mice. Also cells could not be detected after 48 h.
However, 2 months after transplantation, GFP-stained
cells were detected in recipient mice and some of theses. Dual immunostaining for BrdU (green) and MVH (red) of GSCs
Untreated control (b) Chemoablated group (negative control) (c)
, C, D: Scale bars = 50 μm; insets = 10 μm; B: Scale bars = 100 μm
Fig. 7 a Comparison of GSCs in ovaries of untreated control, chemoablated group or EnSCs-treated mice (mean ± standard error, n = 4–5 mice
per data point, *P <0.01). b A schematics showed timing of chemotherapy, transplantation, cyclicity resumed, GFP (+) cells, GSCs (+) cells and
FSHR (+) cells detected
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indicated by human FSHR and GFP double-staining. A
previous study suggests that cyclophosphamide (CTX)
metabolites may induce apoptosis of granulosa cells and
induce ovarian toxicity [4]. Thus, inflammatory signals in-
duced by chemotherapy may “home” EnSCs to sites of
ovarian injury and transdifferentiate into granulosa cells.
We have published similar results using either human am-
niotic fluid cells transplanted by cell injections into dam-
aged ovaries or using human amniotic epithelial cells
transplanted by the tail vein to restore ovarian function.
Both treatments restored ovarian function and grafted
cells were detected in recipient ovaries [15, 16]. However,
more evidence is needed to explain how EnSCs differenti-
ate into granulosa cells.
The importance of proliferative germ cells for replen-
ishing postnatal follicle pools has been verified with bu-
sulfan, a germ-cell toxicant widely used in spermatogonial
stem-cell characterization in male mice. Busulfan could
specifically target GSCs and spermatogonia and lead to
spermatogenic failure in the testis [39-41]. Further studies
showed that a single injection of busulfan (30 mg/kg, ip)
plus cyclophosphamide (120 mg/kg) (B/C) was sufficient
to sterilize female mice and that the resultant germ cell
depletion was irreversible [36]. Recently, the identificationand isolation of female GSCs from mouse and human
ovaries supports the concept that mammalian ovaries gen-
erate new oocytes and follicles during the reproductive
period [27, 29]. To elucidate the biology of female GSCs
induced by B/C treatment, we firstly measured the distri-
bution of GSCs and documented follicular stages in differ-
ent animal treatment groups. Consistent with previous
reports [28], we observed that GSCs were near the ovarian
surface. Histomorphometric studies in 8-week-old female
mice revealed the presence of 78 ± 8 such cells per ovary
and these cells decreased as mice aged (Fig. 7).
B/C treatment destroys the GSCs pool, GSCs pools in
ovaries of sterilized females decreased 64 % one week
after chemotherapy with complete GSCs loss occurring
8 weeks after chemotherapy (Fig. 7). However, if EnSCs
were transplanted a week after chemoablation, GSCs de-
pletion was attenuated. This suggests that EnSCs trans-
plantation restores GSCs pools. Folliculogenesis requires
a carefully orchestrated cross talk between germ cells
and the surrounding somatic cells, however, chemother-
apy could destruct the ovarian niches, decrease granu-
losa cell function and induce ovarian toxicity [1-4].
Herein, we observed that some transplanted stem cells
differentiated into granulosa cells which existed in the
location of cumulus cells (Fig. 5 and Additional file 4:
Lai et al. Journal of Translational Medicine  (2015) 13:155 Page 12 of 13Figure S3). Cumulus cells are a specialized type of gran-
ulosa cell, distinct from the mural granulosa cells that
line the antrum in developing follicles. Cumulus cells
were considered to play a critical role in the reproduct-
ive potential of oocytes and embryos [42]. Although
fewer than 20 % GFP+/human FSHR+ cells were de-
tected in the EnSCs transplantation group (Additional
file 2: Table S2), improvements such as restoration of
cumulus cells may improve the ovarian niche, stimulate
renewal of GSCs or activate primodial follicles then lead
to follicle development. Also, EnSCs, as MSCs, may have
a role in improving damaged immune systems via a
paracrine mechanism [43]. Further research is warranted
to investigate the mechanisms.
Follicle counts conducted after B/C treatment reveal
vastly reduced primordial, primary and secondary follicles,
whereas EnSCs transplantation recovered the reserve
of primordial and growing follicles (Additional file 6:
Figure S5). No evidence exists to suggest that EnSCs
can differentiate into GSCs or oocytes in recipient mice.
Herein the GSCs pool and primordial and growing folli-
cles after EnSCs transplantation did not approach those
numbers in normal female mice of the same age. This
observation may explain why EnSCs transplantation
did not completely restore fertility in chemotherapy-
induced sterilized mice.
Menstrual blood-derived MSCs are attractive because
they are easy to collect (compared to bone marrow as-
piration), have longevity in culture, and can be subcul-
tured to 10–20 passages with retention of a normal
karyotype. We observed that these cells retained multi-
potency as evidenced by their ability to differentiate into
adipocytes, chondroblasts, and osteoblasts (Fig. 1). These
cells are currently being assessed in diverse applications
as an allogeneic immunologically naive cell source [32,
33]. Finally, these cells can be harvested from women
during their child-bearing years, offering up to 12 oppor-
tunities a year for collection. This would offer re-
searchers ample time to collect and store cells for
multiple reproductive therapies, including POF induced
by chemotherapy.Conclusions
EnSCs derived from human menstrual blood have char-
acteristics of MSCs which is able to undergo multipotent
differentiation under specific conditions. As an autolo-
gous cell source of stem cells, EnSCs transplantation
may be a suitable clinical strategy for preserving ovarian
function or fertility in POF/POI patients induced by
chemotherapy.Additional files
Below is the link to the electronic supplementary material.Additional file 1: Figure S1. Histological evaluations of major organs in
untreated control and normal control animals by HE staining. A1) Normal
cardiac fibroblasts. A2) Edematous cardiac fibroblasts 7 days after
chemotherapy. A3) Edematous cardiac fibroblasts 14 days after
chemotherapy. B1) Normal glomerular and tubular structure. B2)
Congestion of tubular structure with glomerular atrophy 7 days after
chemotherapy. B3) Kidney restoration 14 days after chemotherapy. C1)
Normal histological liver division into lobules (the center of the lobule is
the central vein) (V). C2) Edema and congestion in mesenchymal and
inflammatory cell infiltration in liver C3) Recovered liver tissue 14 days
after chemotherapy. D1) The spleen is a large lymphoid organ comprised
of “white pulp” (arrow) and “red pulp” (arrowhead) respectively. D2)
Spleen lymphocytes proliferated after chemotherapy. D3) Restoration of
spleen tissue 14 days after chemotherapy. E1) Normal ovarian tissue. E2)
Atretic follicles (arrow) and fibrosis in the damaged ovary 7 days after
chemotherapy. E3) Extensive fibrosis in the ovarian stroma 14 days after
chemotherapy. Magnification, 100×.
Additional file 2 Table S1. Summary of female fertility study. Table S2.
Quantification of GFP+ cells detected in different groups.
Additional file 3: Figure S2 Negative control image for GFP, Human
nuclear antigen, and human FSHR. A) Human nuclear antigen and GFP
were not detected in untreated controls. B) Human FSHR and GFP were
not detected in normal controls. Scale bars = 100 μm.
Additional file 4: Figure S3. Grafted cells detected by
immunochemistry against human FSHR antigens 2 months after EnSCs
transplantation. (A) Human FSHR was not detected in untreated control
ovaries without EnSCs transplantation. (B) Human FSHR was not detected
in normal control ovaries. (C, D) Human FSHR were detected in recipient
ovaries 2 months after EnSCs transplantation. Arrows indicated positive
staining. Original magnification, 100× (A, C), 200× (B, D).
Additional file 5: Figure S4. MVH stained cells were observed near the
surface of mouse ovaries (Arrow). Scale bars = 50 μm; insets = 10 μm.
Additional file 6: Figure S5. Follicle counts of primordial, primary,
secondary, and atretic follicles in ovaries of each group, including
untreated control, Chemoablated group and EnSCs-treated animals.
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